Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells

  1. Ewa Grudzien-Nogalska1,
  2. Jacek Jemielity2,
  3. Joanna Kowalska2,
  4. Edward Darzynkiewicz2, and
  5. Robert E. Rhoads1
  1. 1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130-3932, USA
  2. 2Department of Biophysics, Warsaw University, Warsaw, 02-089, Poland

Abstract

Capped RNAs synthesized by in vitro transcription have found wide utility for studying mRNA function and metabolism and for producing proteins of interest. We characterize here a recently synthesized series of cap analogs with improved properties that contain a sulfur substitution for a nonbridging oxygen in either the α-, β-, or γ-phosphate moieties, m2 7,2′-OGpppSG, m2 7,2′-OGppSpG, and m2 7,2′-OGpSppG, respectively. The new compounds were also modified at the 2′-O position of the m7Guo to make them anti-reverse cap analogs (ARCAs), i.e., they are incorporated exclusively in the correct orientation during in vitro transcription. Each of the S-ARCAs exists in two diastereoisomeric forms (D1 and D2) that can be resolved by reverse-phase HPLC. A major in vivo pathway for mRNA degradation is initiated by removal of the cap by the pyrophosphatase Dcp1/Dcp2, which cleaves between the α- and β-phosphates. Oligonucleotides capped with m2 7,2′-OGppSpG (D2) were completely resistant to hydrolysis by recombinant human Dcp2 in vitro, whereas those capped with m2 7,2′-OGppSpG (D1) and both isomers of m2 7,2′-OGpppSG were partially resistant. Luciferase mRNA capped with m2 7,2′-OGppSpG (D2) had a t 1/2 of 257 min in cultured HC11 mammary epithelial cells compared with 86 min for m7Gp3G-capped mRNA. Luciferase mRNAs capped with m2 7,2′-OGppSpG (D1) and m2 7,2′-OGppSpG (D2) were translated 2.8-fold and 5.1-fold, respectively, more efficiently in HC11 cells than those capped with m7Gp3G. The greater yield of protein due to combining higher translational efficiency with longer t 1/2 of mRNA should benefit applications that utilize RNA transfection such as protein production, anti-cancer immunization, and gene therapy.

Keywords

Footnotes

  • Reprint requests to: Robert E. Rhoads, Department of Biochemistry and Molecular Biology, LA State University Health Sciences Center, Shreveport, LA 71130-3932, USA; e-mail: rrhoad{at}lsuhsc.edu; fax: (318) 675-5180.

  • Article published online ahead of print. Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.701307.

    • Received June 24, 2007.
    • Accepted July 23, 2007.
« Previous | Next Article »Table of Contents